The global Peptide CDMO Services market size is predicted to grow from US$ 4700 million in 2025 to US$ 11160 million in 2031; it is expected to grow at a CAGR of 15.5% from 2025 to 2031.
Peptide CDMO Services refer to the specialized contract development and manufacturing services offered by third-party organizations to assist pharmaceutical companies in the production of peptide-based therapeutics. These services typically include peptide synthesis, purification, formulation, and analytical testing to ensure that the peptides meet required quality, purity, and stability standards. CDMOs in this sector provide the expertise and infrastructure needed for large-scale production, offering cost-effective solutions and faster time-to-market for peptide drugs. With the growing demand for personalized medicines and the increasing role of peptides in treating various diseases, including cancer, diabetes, and neurological disorders, peptide CDMOs play a crucial role in the development and manufacturing of peptide therapeutics.
The demand for Peptide CDMO (Contract Development and Manufacturing Organization) services is driven by the growing focus on peptide-based therapeutics in the pharmaceutical industry. Peptides are becoming increasingly important in treating a wide range of diseases, including cancer, endocrine disorders, neurological conditions, and autoimmune diseases, due to their ability to offer high specificity, targeted delivery, and fewer side effects compared to traditional small molecules. As the complexity of peptide drugs increases, pharmaceutical companies are increasingly outsourcing the development and manufacturing of these drugs to Peptide CDMOs, which offer specialized expertise, advanced technologies, and scalable production capabilities. This trend is amplified by the rise in biopharmaceutical outsourcing, with companies looking to reduce time-to-market and costs while focusing on their core competencies in research and development.Despite the growing demand for peptide CDMO services, the market faces challenges related to the complexity and cost of peptide synthesis and manufacturing. Peptides often require specialized technologies for synthesis, purification, and formulation, which can make the process both expensive and time-consuming. The production of high-quality peptides at large scale involves significant technical hurdles, such as ensuring purity, stability, and yield, which increases operational costs for CDMOs. Additionally, regulatory hurdles pose a challenge, as peptides often require more stringent oversight compared to traditional drugs. This includes the need for comprehensive documentation, clinical trials, and compliance with GMP (Good Manufacturing Practices). These factors may limit the ability of some smaller CDMOs to compete effectively, making it difficult for them to meet the increasing demand while ensuring high-quality standards..
The 鈥淧eptide CDMO Services Industry Forecast鈥� looks at past sales and reviews total world Peptide CDMO Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Peptide CDMO Services sales for 2025 through 2031. With Peptide CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide CDMO Services industry.
This Insight Report provides a comprehensive analysis of the global Peptide CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Peptide CDMO Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide CDMO Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide CDMO Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
APIs and Intermediates
FDF
Segmentation by Application:
Commercial
Academic Research
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Peptide CDMO Services 麻豆原创 Size (2020-2031)
2.1.2 Peptide CDMO Services 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Peptide CDMO Services by Country/Region (2020, 2024 & 2031)
2.2 Peptide CDMO Services Segment by Type
2.2.1 APIs and Intermediates
2.2.2 FDF
2.3 Peptide CDMO Services 麻豆原创 Size by Type
2.3.1 Peptide CDMO Services 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Peptide CDMO Services 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Peptide CDMO Services Segment by Application
2.4.1 Commercial
2.4.2 Academic Research
2.4.3 Other
2.5 Peptide CDMO Services 麻豆原创 Size by Application
2.5.1 Peptide CDMO Services 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Peptide CDMO Services 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Peptide CDMO Services 麻豆原创 Size by Player
3.1 Peptide CDMO Services 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Peptide CDMO Services Revenue by Player (2020-2025)
3.1.2 Global Peptide CDMO Services Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Peptide CDMO Services Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Peptide CDMO Services by Region
4.1 Peptide CDMO Services 麻豆原创 Size by Region (2020-2025)
4.2 Global Peptide CDMO Services Annual Revenue by Country/Region (2020-2025)
4.3 Americas Peptide CDMO Services 麻豆原创 Size Growth (2020-2025)
4.4 APAC Peptide CDMO Services 麻豆原创 Size Growth (2020-2025)
4.5 Europe Peptide CDMO Services 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Peptide CDMO Services 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Peptide CDMO Services 麻豆原创 Size by Country (2020-2025)
5.2 Americas Peptide CDMO Services 麻豆原创 Size by Type (2020-2025)
5.3 Americas Peptide CDMO Services 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide CDMO Services 麻豆原创 Size by Region (2020-2025)
6.2 APAC Peptide CDMO Services 麻豆原创 Size by Type (2020-2025)
6.3 APAC Peptide CDMO Services 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Peptide CDMO Services 麻豆原创 Size by Country (2020-2025)
7.2 Europe Peptide CDMO Services 麻豆原创 Size by Type (2020-2025)
7.3 Europe Peptide CDMO Services 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peptide CDMO Services by Region (2020-2025)
8.2 Middle East & Africa Peptide CDMO Services 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Peptide CDMO Services 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Peptide CDMO Services 麻豆原创 Forecast
10.1 Global Peptide CDMO Services Forecast by Region (2026-2031)
10.1.1 Global Peptide CDMO Services Forecast by Region (2026-2031)
10.1.2 Americas Peptide CDMO Services Forecast
10.1.3 APAC Peptide CDMO Services Forecast
10.1.4 Europe Peptide CDMO Services Forecast
10.1.5 Middle East & Africa Peptide CDMO Services Forecast
10.2 Americas Peptide CDMO Services Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Peptide CDMO Services Forecast
10.2.2 Canada 麻豆原创 Peptide CDMO Services Forecast
10.2.3 Mexico 麻豆原创 Peptide CDMO Services Forecast
10.2.4 Brazil 麻豆原创 Peptide CDMO Services Forecast
10.3 APAC Peptide CDMO Services Forecast by Region (2026-2031)
10.3.1 China Peptide CDMO Services 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Peptide CDMO Services Forecast
10.3.3 Korea 麻豆原创 Peptide CDMO Services Forecast
10.3.4 Southeast Asia 麻豆原创 Peptide CDMO Services Forecast
10.3.5 India 麻豆原创 Peptide CDMO Services Forecast
10.3.6 Australia 麻豆原创 Peptide CDMO Services Forecast
10.4 Europe Peptide CDMO Services Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Peptide CDMO Services Forecast
10.4.2 France 麻豆原创 Peptide CDMO Services Forecast
10.4.3 UK 麻豆原创 Peptide CDMO Services Forecast
10.4.4 Italy 麻豆原创 Peptide CDMO Services Forecast
10.4.5 Russia 麻豆原创 Peptide CDMO Services Forecast
10.5 Middle East & Africa Peptide CDMO Services Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Peptide CDMO Services Forecast
10.5.2 South Africa 麻豆原创 Peptide CDMO Services Forecast
10.5.3 Israel 麻豆原创 Peptide CDMO Services Forecast
10.5.4 Turkey 麻豆原创 Peptide CDMO Services Forecast
10.6 Global Peptide CDMO Services Forecast by Type (2026-2031)
10.7 Global Peptide CDMO Services Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Peptide CDMO Services Forecast
11 Key Players Analysis
11.1 Bachem
11.1.1 Bachem Company Information
11.1.2 Bachem Peptide CDMO Services Product Offered
11.1.3 Bachem Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Bachem Main Business Overview
11.1.5 Bachem Latest Developments
11.2 PolyPeptide
11.2.1 PolyPeptide Company Information
11.2.2 PolyPeptide Peptide CDMO Services Product Offered
11.2.3 PolyPeptide Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 PolyPeptide Main Business Overview
11.2.5 PolyPeptide Latest Developments
11.3 CordenPharma
11.3.1 CordenPharma Company Information
11.3.2 CordenPharma Peptide CDMO Services Product Offered
11.3.3 CordenPharma Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 CordenPharma Main Business Overview
11.3.5 CordenPharma Latest Developments
11.4 AmbioPharm
11.4.1 AmbioPharm Company Information
11.4.2 AmbioPharm Peptide CDMO Services Product Offered
11.4.3 AmbioPharm Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 AmbioPharm Main Business Overview
11.4.5 AmbioPharm Latest Developments
11.5 USV Peptides
11.5.1 USV Peptides Company Information
11.5.2 USV Peptides Peptide CDMO Services Product Offered
11.5.3 USV Peptides Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 USV Peptides Main Business Overview
11.5.5 USV Peptides Latest Developments
11.6 Thermofischer
11.6.1 Thermofischer Company Information
11.6.2 Thermofischer Peptide CDMO Services Product Offered
11.6.3 Thermofischer Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Thermofischer Main Business Overview
11.6.5 Thermofischer Latest Developments
11.7 Bio Basic
11.7.1 Bio Basic Company Information
11.7.2 Bio Basic Peptide CDMO Services Product Offered
11.7.3 Bio Basic Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Bio Basic Main Business Overview
11.7.5 Bio Basic Latest Developments
11.8 JPT
11.8.1 JPT Company Information
11.8.2 JPT Peptide CDMO Services Product Offered
11.8.3 JPT Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 JPT Main Business Overview
11.8.5 JPT Latest Developments
11.9 Genscript
11.9.1 Genscript Company Information
11.9.2 Genscript Peptide CDMO Services Product Offered
11.9.3 Genscript Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Genscript Main Business Overview
11.9.5 Genscript Latest Developments
11.10 Xinbang Pharma
11.10.1 Xinbang Pharma Company Information
11.10.2 Xinbang Pharma Peptide CDMO Services Product Offered
11.10.3 Xinbang Pharma Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Xinbang Pharma Main Business Overview
11.10.5 Xinbang Pharma Latest Developments
11.11 ScinoPharm
11.11.1 ScinoPharm Company Information
11.11.2 ScinoPharm Peptide CDMO Services Product Offered
11.11.3 ScinoPharm Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 ScinoPharm Main Business Overview
11.11.5 ScinoPharm Latest Developments
11.12 SN Biopharm
11.12.1 SN Biopharm Company Information
11.12.2 SN Biopharm Peptide CDMO Services Product Offered
11.12.3 SN Biopharm Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 SN Biopharm Main Business Overview
11.12.5 SN Biopharm Latest Developments
11.13 CBL
11.13.1 CBL Company Information
11.13.2 CBL Peptide CDMO Services Product Offered
11.13.3 CBL Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 CBL Main Business Overview
11.13.5 CBL Latest Developments
11.14 Piramal Pharma
11.14.1 Piramal Pharma Company Information
11.14.2 Piramal Pharma Peptide CDMO Services Product Offered
11.14.3 Piramal Pharma Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Piramal Pharma Main Business Overview
11.14.5 Piramal Pharma Latest Developments
11.15 CPC Scientific
11.15.1 CPC Scientific Company Information
11.15.2 CPC Scientific Peptide CDMO Services Product Offered
11.15.3 CPC Scientific Peptide CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 CPC Scientific Main Business Overview
11.15.5 CPC Scientific Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
